Sunday, July 02, 2006

Abraxane™ Approved by FDA for Breast Cancer

The FDA has approved Abraxane™ (paclitaxel protein-bound particles for injectable suspension) in metastatic breast cancer. Abraxane™ is used in patients who have failed combination therapy or who have relapsed six months after adjuvant chemotherapy. Approving this drug has created “protein-bound particle” drugs with Abraxane™ leading as the first in this class. American Bioscience, Inc. (ABI) has made this possible with its proprietary nanoparticle albumin-bound (nab) technology. --Click the title of this post to read the full article from its source--


Post a Comment

<< Home

/* WebRing Code */